TECSPIRET Trademark

Trademark Overview


On Friday, March 26, 2021, a trademark application was filed for TECSPIRET with the United States Patent and Trademark Office. The USPTO has given the TECSPIRET trademark a serial number of 90606383. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, December 16, 2022. This trademark is owned by Biohaven Pharmaceutical Holding CompanyLtd.. The TECSPIRET trademark is filed in the Pharmaceutical Products category with the following description:

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Scler...
tecspiret

General Information


Serial Number90606383
Word MarkTECSPIRET
Filing DateFriday, March 26, 2021
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, December 16, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 14, 2021

Trademark Statements


Goods and ServicesMedicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, December 16, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiohaven Pharmaceutical Holding CompanyLtd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressTortola VG1110
VG

Party NameBiohaven Pharmaceutical Holding CompanyLtd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Trademark Events


Event DateEvent Description
Friday, December 16, 2022ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, December 16, 2022ABANDONMENT - AFTER PUBLICATION
Thursday, December 15, 2022TEAS EXPRESS ABANDONMENT RECEIVED
Friday, October 28, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 28, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 18, 2022SOU EXTENSION 1 GRANTED
Monday, July 18, 2022SOU EXTENSION 1 FILED
Monday, July 18, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, February 8, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 14, 2021PUBLISHED FOR OPPOSITION
Wednesday, November 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 3, 2021ASSIGNED TO EXAMINER
Friday, July 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 30, 2021NEW APPLICATION ENTERED